Neuralstem Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
110.00
18.80
10.40
16.20
260.00
260
SG&A Expense
12,389.20
17,106.10
18,821.50
19,845.60
13,185.90
8,333.70
EBIT
12,523.90
17,435.90
-
20,166.80
13,215.10
8,259.50
Unusual Expense
964.50
3,639.80
-
190.30
1,470.20
3,269.10
Non Operating Income/Expense
5,017.20
-
0.70
15.60
891.90
5.40
Interest Expense
1,394.30
1,620.80
1,816.20
1,141.30
159.10
7.70
Pretax Income
19,831.90
22,628.70
20,903.90
21,074.60
15,666.00
4,924.60
Consolidated Net Income
19,831.90
22,628.70
20,903.90
21,074.60
15,666.00
4,924.60
Net Income
19,831.90
22,628.70
20,903.90
21,074.60
15,666.00
4,924.60
Net Income After Extraordinaries
19,831.90
22,628.70
20,903.90
21,074.60
15,666.00
4,924.60
Net Income Available to Common
19,831.90
22,628.70
20,903.90
21,074.60
15,666.00
4,924.60
EPS (Basic)
3.57
3.38
2.99
2.53
1.20
0.32
Basic Shares Outstanding
5,559.90
6,699.00
6,989.80
8,346.00
13,064.40
15,156.90
EPS (Diluted)
3.57
3.38
2.99
2.53
1.20
0.32
Diluted Shares Outstanding
5,559.90
6,699.00
6,989.80
8,346.00
13,064.40
15,156.90
EBITDA
12,279.20
17,087.20
18,811.10
19,829.30
12,925.90
8,073.70
Non-Operating Interest Income
68.00
67.70
69.50
58.80
70.30
78.80

About Neuralstem

View Profile
Address
20271 Goldenrod Lane
Germantown Maryland 20876
United States
Employees -
Website http://www.neuralstem.com
Updated 07/08/2019
Neuralstem, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel and proprietary chemical entity screening platform. The company was founded by I.